JB-101

Phase 2Biologic

JJuntendo University

JB-101 is one of 7 biologic programs targeting Tolerance. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ToleranceActive, not recruiting

TolerancePhase 2

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Tolerance

#DrugCompanyPhaseTrials

Avigan

AAppili Therapeutics Inc.

Phase 2

2 2

Experimental

Biogen

Preclinical

1 3

JB-101

JJuntendo University

Phase 2

1 4

Levo-Dromoran

VValeant Pharmaceuticals

Preclinical

1 5

Siplizumab

UUniversity of Alabama at Birmingham

Preclinical

—6

Oxytocin Treatment

UUniversity of Electronic Science and Technology of China

Preclinical

1 7

Tazorac

FFougera Pharmaceuticals Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tolerance1 trial

Induction of Transplant Tolerance in LDLT Via iTS

Active, not recruiting·JJuntendo University·Phase 1/2·NCT04950842·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for JB-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JB-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JB-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Juntendo University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: JJuntendo University

JB-101

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tolerance1 trial

References

Drug Info

Quick Facts

Related News